Skip to content

Study · Not a test of the peptide alone · 2006

2 results

Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree.

Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Alonso MJ

Journal of controlled release : official journal of the Controlled Release Society14 Feb 2006Cited by 176 (Europe PMC)

PMID16481062 (opens in a new tab)DOI10.1016/j.jconrel.2005.12.015 (opens in a new tab)PepBankPUB-16481062
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Calcitonin-salmon.

  1. 01AnimalNot a test of Calcitonin-salmon aloneAnimal study (in vivo)Pharmacokinetics

    In the in vivo model, chitosan-PEG nanocapsules enhanced intestinal absorption of salmon calcitonin.

    In plain wordsIn animals, chitosan-PEG nanocapsules enhanced intestinal absorption of salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseIntestinal absorption
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Finally, the results of the in vivo studies showed the capacity of chitosan-PEG nanocapsules to enhance and prolong the intestinal absorption of salmon calcitonin.
    1 context sentence
    Summary · context
    In the present work, our goal was to design a new type of nanocapsules, using chitosan chemically modified with poly(ethylene glycol) (PEG) (0.5% and 1% pegylation degree) and to investigate the consequences of this modification on the in vitro and in vivo behaviour of the nanocapsules.

    In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Calcitonin-salmon.

  2. 02AnimalNot a test of Calcitonin-salmon aloneAnimal study (in vivo)Pharmacokinetics

    In the in vivo model, chitosan-PEG nanocapsules prolonged intestinal absorption of salmon calcitonin.

    In plain wordsIn animals, chitosan-PEG nanocapsules prolonged intestinal absorption of salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseIntestinal absorption duration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Finally, the results of the in vivo studies showed the capacity of chitosan-PEG nanocapsules to enhance and prolong the intestinal absorption of salmon calcitonin.
    1 context sentence
    Summary · context
    In the present work, our goal was to design a new type of nanocapsules, using chitosan chemically modified with poly(ethylene glycol) (PEG) (0.5% and 1% pegylation degree) and to investigate the consequences of this modification on the in vitro and in vivo behaviour of the nanocapsules.

    In this study, Calcitonin-salmon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Calcitonin-salmon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.